Pitcairn Co. grew its position in Celgene Co. (NASDAQ:CELG) by 78.6% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,192 shares of the biopharmaceutical company’s stock after purchasing an additional 3,606 shares during the period. Pitcairn Co.’s holdings in Celgene were worth $1,194,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Thompson Davis & CO. Inc. boosted its holdings in shares of Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after acquiring an additional 43 shares in the last quarter. Arcadia Investment Management Corp MI boosted its holdings in shares of Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 400 shares in the last quarter. Guidant Wealth Advisors acquired a new stake in Celgene during the third quarter valued at approximately $119,000. Motco lifted its stake in Celgene by 19.3% during the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 159 shares during the last quarter. Finally, Penserra Capital Management LLC acquired a new stake in Celgene during the second quarter valued at approximately $129,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.
Celgene Co. (NASDAQ:CELG) opened at $106.00 on Tuesday. Celgene Co. has a 12 month low of $94.55 and a 12 month high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. The stock has a market cap of $83,460.00, a price-to-earnings ratio of 25.00, a P/E/G ratio of 0.68 and a beta of 1.77.
CELG has been the subject of several recent research reports. Royal Bank of Canada cut their target price on shares of Celgene from $166.00 to $148.00 and set a “top pick” rating for the company in a research note on Friday, October 27th. Leerink Swann restated a “buy” rating and issued a $156.00 price target on shares of Celgene in a research report on Friday, October 20th. Morgan Stanley reduced their price target on shares of Celgene from $120.00 to $115.00 and set an “underweight” rating for the company in a research report on Monday, October 23rd. SunTrust Banks reduced their price target on shares of Celgene from $156.00 to $127.00 and set a “buy” rating for the company in a research report on Friday, October 27th. Finally, William Blair restated an “outperform” rating on shares of Celgene in a research report on Friday, October 20th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and nineteen have assigned a buy rating to the stock. Celgene presently has a consensus rating of “Buy” and a consensus target price of $131.18.
ILLEGAL ACTIVITY NOTICE: “Pitcairn Co. Boosts Holdings in Celgene Co. (NASDAQ:CELG)” was published by BBNS and is the property of of BBNS. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/pitcairn-co-raises-stake-in-celgene-co-celg/1819517.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.